Active — Not RecruitingPhase 2

Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

United States10 participantsStarted 2025-02-20

Plain-language summary

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * diagnosis of idiopathic subglottic stenosis Exclusion Criteria: * History of active or latent tuberculosis infection * History of inflammatory bowel disease * Pregnancy or lactation * Known allergic reactions to study drug * Disease involving the vocal cords * Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency

What they're measuring

Number of weeks between operative interventions

Timeframe: From baseline up to 12 months.

Trial details

NCT IDNCT05309616

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Idiopathic Subglottic Stenosis trials